News

Who will get cancer treatment-induced cardiotoxicity?


 

AT THE HFSA ANNUAL SCIENTIFIC MEETING

References

“There is a real opportunity here to improve the care of cancer patients and prevent heart failure,” Dr. Lenihan concluded.

He reported receiving research support from Singulex, Millenium, and Acorda as well as serving as a consultant to Onyx and Roche.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

What about LCZ696 for heart failure with preserved ejection fraction?
MDedge Family Medicine
Should LCZ696 receive a level I indication?
MDedge Family Medicine
CardioMEMS heralds new proactive era in heart failure management
MDedge Family Medicine
Myocardial geometry, function altered in obese children
MDedge Family Medicine
Heart failure hospitalizations jump after major holidays
MDedge Family Medicine
Hospitalists shine in study of heart failure outcomes
MDedge Family Medicine
Advanced practice registered nurses in cardiology
MDedge Family Medicine
Androgen-deprivation therapy linked to cardiac death
MDedge Family Medicine
Four lifestyle changes might prevent 40% of heart failure
MDedge Family Medicine
Cancer treatment–induced cardiotoxicity greatly underappreciated
MDedge Family Medicine